| (Values in U.S. Thousands) | Sep, 2025 | Sep, 2024 | Sep, 2023 | Sep, 2022 | Sep, 2021 |
| Sales | 23,375,000 | 22,363,000 | 21,680,000 | 21,714,000 | 17,997,000 |
| Sales Growth | +4.53% | +3.15% | -0.16% | +20.65% | +24.46% |
| Net Income | 2,144,000 | 1,942,000 | 1,509,000 | 2,038,000 | 1,727,000 |
| Net Income Growth | +10.40% | +28.69% | -25.96% | +18.01% | +22.40% |
Siemens Healthineers Ag (SHL.D.DX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [DXE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2024) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (17% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (20%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. Americas represents 42% of total sales, Europe, Middle East, and Africa 33%, and Asia-Pacific including China the remainder.
Fiscal Year End Date: 09/30